Head and Neck Cancer Therapeutics Market Size, Share & Trends Report

Head and Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By Region, And Segment Forecasts, 2016 - 2022

  • Report ID: GVR-2-68038-125-2
  • Number of Pages: 79
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Table Of Contents

Chapter 1 Research Methodology
                 1.1 Information procurement
                 1.2 Information or Data Analysis
                     1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                 3.1 Disease Primer
                     3.1.1 Types:
                         3.1.1.1 Oral and Oropharyngeal Cancer
                         3.1.1.2 Laryngeal and Hypopharyngeal Cancer
                         3.1.1.3 Nasopharyngeal Cancer
                         3.1.1.4 Nasal Cavity and Paranasal Sinus Cancer
                         3.1.1.5 Salivary Gland Cancer
                 3.2 Epidemiology by Indications
                     3.2.1 Oral Cavity Cancers
                     3.2.2 Oropharyngeal Cancers
                     3.2.3 Lip Cancers
                     3.2.4 Salivary Gland Cancers
                     3.2.5 Nasopharyngeal Cancers
                     3.2.6 Hypopharyngeal Cancers
                 3.3 Current Prevalence Rate and Numbers for Seven Major Markets (U.S., Japan, EU5)
                 3.4 Current Incidence Rate and Numbers for Seven Major Markets (U.S., Japan, EU5)
Chapter 4 Global Head and Neck Cancer Drugs Market Overview
                 4.1 Market by Treatment
                     4.1.1 Surgery
                     4.1.2 Radiation Therapy
                     4.1.3 Chemotherapy
                     4.1.4 Immunotherapy
                 4.2 Market by Therapeutic Class
                     4.2.1 PD Inhibitors
                     4.2.2 EGFR Inhibitors
                     4.2.3 Microtubule Inhibitors
                 4.3 Market Size & Forecast
                 4.4 Sales Performance
                     4.4.1 Sales Performance, by Drug Class (2016 - 2022)
                     4.4.2 Sales Performance, by Region (2016 - 2022)
                     4.4.3 Sales Performance, by Company (2016 - 2022)
                 4.5 Market Share Distribution
                 4.6 Market Dynamics among Leading Brands
                 4.7 Patent Expiry Schedule
                 4.8 Drivers and Challenges
                     4.8.1 Drivers
                     4.8.2 Challenges
                 4.9 M&A, Deal Landscape (2013-2017 YTD)
                 4.10 Pricing and Reimbursement
                 4.11 Biosimilar Evolution
                 4.12 Emerging Markets
                 4.13 SWOT
Chapter 5 Head and Neck Cancer Drugs Market: Pipeline Intelligence
                 5.1 Pipeline Landscape
                     5.1.1 Leading Drugs in Development
                     5.1.2 Key R&D Trends
                 5.2 Promising Drug Candidates in Pipeline
                     5.2.1 Late Stage Pipeline Analysis
                     5.2.2 Profile of Disruptive Drugs
                         5.2.2.1 Opdivo (nivolumab)
                         5.2.2.2 Keytruda (pembrolizumab)
                         5.2.2.3 Imfinzi (durvalumab)
                         5.2.2.4 Bavencio (avelumab)
                         5.2.2.5 Yervoy (ipilimumab)
                         5.2.2.6 Tremelimumab
                         5.2.2.7 Buparlisib
                         5.2.2.8 Epacadostat
                 5.3 Global Pipeline Forecast
Chapter 6 Competitive Landscape
                 6.1 Bristol-Myers Squibb
                     6.1.1 Company Overview
                     6.1.2 Current Product Portfolio
                     6.1.3 Product Forecast Sales up to 2022
                     6.1.4 Strategic Initiatives (Bristol-Myers Squibb)
                         6.1.4.1 Key Company News Flow
                     6.1.5 Pipeline Analysis & Overview
                     6.1.6 Catalysts & Events Calendar
                     6.1.7 SWOT
                 6.2 Merck
                     6.2.1 Company Overview
                     6.2.2 Current Product Portfolio
                     6.2.3 Product Forecast Sales up to 2022
                     6.2.4 Strategic Initiatives (Merck)
                         6.2.4.1 Key Company News Flow
                     6.2.5 Pipeline Analysis & Overview
                     6.2.6 Catalysts & Events Calendar
                     6.2.7 SWOT
                 6.3 Sanofi
                     6.3.1 Company Overview
                     6.3.2 Current Product Portfolio
                     6.3.3 Product Forecast Sales up to 2022
                     6.3.4 Strategic Initiatives (Sanofi)
                         6.3.4.1 Key Company News Flow
                     6.3.5 Pipeline Analysis & Overview
                     6.3.6 Catalysts & Events Calendar
                     6.3.7 SWOT
                 6.4 Eli Lilly
                     6.4.1 Company Overview
                     6.4.2 Current Product Portfolio
                     6.4.3 Product Forecast Sales up to 2022
                     6.4.4 Strategic Initiatives (Eli Lilly)
                         6.4.4.1 Key Company News Flow
                     6.4.5 Pipeline Analysis & Overview
                     6.4.6 Catalysts & Events Calendar
                     6.4.7 SWOT
Chapter 7 Market Outlook
                 7.1 What the Future Holds
                 7.2 Winners and Losers
                     7.2.1 Winners
                     7.2.2 Losers
                 7.3 Emerging Companies
                 7.4 The Road Ahead

 


List of Tables

TABLE 1 Current Prevalence Rate and Numbers across Seven Major Markets - 2015
TABLE 2 Current Incidence Rates and Numbers across Seven Major Markets - 2016
TABLE 3 Sales Performance, by Drug Class (in USD Million)
TABLE 4 Sales Performance, by Region (in USD Million)
TABLE 5 U.S. Sales by Therapeutic Class (in USD Million)
TABLE 6 Japan Sales by Therapeutic Class (in USD Million)
TABLE 7 U.K. Sales by Therapeutic Class (in USD Million)
TABLE 8 Germany Sales by Therapeutic Class (in USD Million)
TABLE 9 Spain Sales by Therapeutic Class (in USD Million)
TABLE 10 France Sales by Therapeutic Class (in USD Million)
TABLE 11 Italy Sales by Therapeutic Class (in USD Million)
TABLE 12 Sales Performance, by Company (in USD Million)
TABLE 13 Patent Expiry Schedule
TABLE 14 Taxotere (Docetaxel) Biosimilars
TABLE 15 Erbitux (Cetuximab) Biosimilars in Pipeline
TABLE 16 R&D Pipeline Overview
TABLE 17 Other Drugs in Pipeline
TABLE 18 Late Stage Pipeline
TABLE 19 Product Profile: Opdivo (nivolumab)
TABLE 20 Product Profile: Keytruda (pembrolizumab)
TABLE 21 Product Profile: Imfinzi (durvalumab)
TABLE 22 Product Profile: Bavencio (avelumab)
TABLE 23 Product Profile: Yervoy (ipilimumab)
TABLE 24 Product Profile: Tremelimumab
TABLE 25 Product Profile: Buparlisib
TABLE 26 Product Profile: Epacadostat
TABLE 27 Global Pipeline Forecast
TABLE 28 Product Portfolio: Opdivo
TABLE 29 Opdivo Sales Forecast, 2016 - 2022 (in USD Million)
TABLE 30 Bristol-Myers Squibb Pipeline
TABLE 31 Events Calendar
TABLE 32 Product Portfolio: Keytruda
TABLE 33 Keytruda Sales Forecast, 2016 - 2022 (in USD Million)
TABLE 34 Merck Pipeline
TABLE 35 Events Calendar
TABLE 36 Product Portfolio: Taxotere
TABLE 37 Taxotere Sales Forecast, 2016 - 2022 (in USD Million)
TABLE 38 Sanofi Pipeline
TABLE 39 Events Calendar
TABLE 40 Product Portfolio: Erbitux
TABLE 41 Erbitux Sales Forecast, 2016 - 2022 (in USD Million)
TABLE 42 Eli Lilly Pipeline
TABLE 43 Events Calendar


List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 5-year Limited Duration Prevalence across Seven Major Markets - 2015
FIG. 8 5-year Limited Duration Prevalence Rates across Seven Major Markets - 2015
FIG. 9 Gender Specific Prevalence across Seven Major Markets - 2015
FIG. 10 Gender Specific Prevalence Rates across Seven Major Markets - 2015
FIG. 11 Current Incidence by Numbers for Seven Major Markets - 2014
FIG. 12 Current Incidence Rates per 100,000 in Seven Major Markets - 2014
FIG. 13 Gender Specific Incidence by Numbers across Seven Major Markets - 2014
FIG. 14 Gender Specific Incidence Rates per 100,000 across Seven Major Markets - 2014
FIG. 15 Head and Neck Cancer Drugs Market Forecast (2016, 2022)
FIG. 16 Head and Neck Cancer Drugs Market by Therapeutic Class (2016, 2022)
FIG. 17 Head and Neck Cancer Drugs Market by Region (2016, 2022)
FIG. 18 Market Share Distribution (2016, 2022)
FIG. 19 Head and Neck Cancer Drugs Market SWOT
FIG. 20 Bristol Myers Squibb SWOT Analysis
FIG. 21 Merck SWOT Analysis
FIG. 22 Sanofi SWOT Analysis
FIG. 23 Eli Lilly SWOT Analysis

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.